# A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients

> **NCT00336310** · PHASE4 · UNKNOWN · sponsor: **National Cheng-Kung University Hospital** · enrollment: 50 (—)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Repaglinide

## Key facts

- **NCT ID:** NCT00336310
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-07
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 50 (—)
- **Last updated:** 2006-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00336310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00336310, "A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00336310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*